MedTrace Logo

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

NCT05008913 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-09-06

No results posted yet for this study

Summary

This is a non-randomised study in patients with advanced solid malignancies

Conditions

Interventions

DRUG

[14C]Adavosertib

Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2021-11-16
Completion
2021-11-16
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008913 on ClinicalTrials.gov